NASDAQ:CAMP CAMP4 Therapeutics Q3 2019 Earnings Results & Report $3.39 +0.10 (+3.04%) Closing price 10/22/2026 04:00 PM EasternExtended Trading$3.47 +0.08 (+2.30%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CAMP4 Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2019 results, released December 20, 2018. The company reported EPS of $5.75 versus the $3.68 consensus estimate, while revenue of $88.50 million topped the $88.26 million estimate by $0.24 million. Revenue decreased 5.5% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2019Report DateDecember 20, 2018TimeAfter Market Closes CAMP4 Therapeutics EPS ResultsActual EPS$5.75Consensus EPS $3.68Beat/MissBeat by +$2.07One Year Ago EPS$7.13EPS Beat Rate3 of last 8 quartersCAMP4 Therapeutics Revenue ResultsActual Revenue$88.50 millionExpected Revenue$88.26 millionBeat/MissBeat by +$240.00 thousandYoY Revenue Growth-5.50%Conference Call ResourcesEarnings HistoryCompany Profile CAMP4 Therapeutics Q3 2019 Earnings FAQ Did CAMP4 Therapeutics beat earnings estimates for Q3 2019? CAMP4 Therapeutics (NASDAQ:CAMP) reported earnings of $5.75 per share for Q3 2019, beating the consensus estimate of $3.68. The report was announced on Thursday, December 20, 2018. What was CAMP4 Therapeutics' revenue for Q3 2019? CAMP4 Therapeutics reported revenue of $88.50 million for Q3 2019, against a consensus estimate of $88.26 million. CAMP4 Therapeutics Earnings HeadlinesCAMP4 Therapeutics (NASDAQ:CAMP) Stock Picked Up by Analysts at Needham & Company LLCOctober 17, 2026 | americanbankingnews.comNeedham & Co Initiates Coverage on CAMP4 Therapeutics With Buy Rating, $8 Price TargetOctober 15, 2026 | marketscreener.comMTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 23 at 1:00 AM | Banyan Hill Publishing (Ad)CAMP4 to Participate in Chardan’s 10th Annual Healthcare ConferenceOctober 14, 2026 | markets.businessinsider.comCAMP4 to Participate in Chardan's 10th Annual Healthcare ConferenceOctober 14, 2026 | globenewswire.comOppenheimer Initiates Coverage on CAMP4 Therapeutics With Outperform Rating, $15 Price TargetOctober 5, 2026 | marketscreener.comMSee More CAMP4 Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CAMP4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CAMP4 Therapeutics and other key companies, straight to your email. Email Address About CAMP4 TherapeuticsCAMP4 Therapeutics (NASDAQ:CAMP) is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them. CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins. Its research programs are aimed at diseases in which restoring or increasing the activity of an underexpressed gene could address the underlying cause of illness. The company’s lead program, CAMP4-001, is being developed for phenylketonuria, an inherited metabolic disorder associated with inadequate activity of the phenylalanine hydroxylase gene. CAMP4 Therapeutics is headquartered in Cambridge, Massachusetts, and is led by President and Chief Executive Officer Josh Mandel-Brehm.View CAMP4 Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Texas Paused Data Center Hookups—2 Power Stocks Are Waiting on the VerdictIs Texas Instruments Setting Up for Its Next Big Breakout?Lam Research's Earnings Beat Wasn't the Real Story—Its 2027 Outlook WasTesla’s Flying-Car Hype Hits an Earnings Reality CheckMeta Bounces Back in Q3, But the Bigger Test Comes in 2027Microsoft's Earnings Problem: Even Great May Not Be EnoughNextEra and Dominion Have a Deal—Now Comes the Hard Part Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
